Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Concurrent outbreaks of circulating vaccine-derived poliovirus serotypes 1 and 2 (cVDPV1, cVDPV2) were confirmed in the Republic of the Philippines in September 2019 and were subsequently confirmed in Malaysia by early 2020. There is continuous population subgroup movement in specific geographies between the two countries. Outbreak response efforts focused on sequential supplemental immunization activities with monovalent Sabin strain oral poliovirus vaccine type 2 (mOPV2) and bivalent oral poliovirus vaccines (bOPV, containing Sabin strain types 1 and 3) as well as activities to enhance poliovirus surveillance sensitivity to detect virus circulation. A total of six cVDPV1 cases, 13 cVDPV2 cases, and one immunodeficiency-associated vaccine-derived poliovirus type 2 case were detected, and there were 35 cVDPV1 and 31 cVDPV2 isolates from environmental surveillance sewage collection sites. No further cVDPV1 or cVDPV2 have been detected in either country since March 2020. Response efforts in both countries encountered challenges, particularly those caused by the global COVID-19 pandemic. Important lessons were identified and could be useful for other countries that experience outbreaks of concurrent cVDPV serotypes.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10546869PMC
http://dx.doi.org/10.1016/j.vaccine.2022.02.022DOI Listing

Publication Analysis

Top Keywords

vaccine-derived poliovirus
12
cvdpv1 cvdpv2
12
concurrent outbreaks
8
outbreaks circulating
8
circulating vaccine-derived
8
republic philippines
8
response efforts
8
sabin strain
8
oral poliovirus
8
poliovirus
6

Similar Publications

Public health response to immunodeficiency-related vaccine-derived poliovirus during a poliovirus outbreak in the Philippines: a case report.

IJID Reg

September 2025

Division of Infectious and Tropical Diseases in Pediatrics, Department of Pediatrics, College of Medicine - Philippine General Hospital, University of the Philippines, Manila, Philippines.

Immunodeficiency-related vaccine-derived poliovirus (iVDPV) was detected in the stool of a 5-year-old male patient with combined immunodeficiency. The patient presented in August 2019 with chronic diarrhea, fever, and generalized weakness. This case was identified concurrently with the 2019-2020 poliovirus outbreak in the Philippines.

View Article and Find Full Text PDF

Despite extensive research, the pathogenesis of Post-Polio Syndrome (PPS) remains unclear. We investigated 251 participants from Northern Italy: long-term polio survivors with PPS, long-term polio survivors with stable polio, family members of both groups, subjects with neurological disorders other than poliomyelitis, and healthy controls. This study investigated whether persistent viral activity or the existence of viral reservoirs contributes to causing PPS.

View Article and Find Full Text PDF

Background: Approximately 1.5 billion doses of novel oral polio vaccine type 2 (nOPV2) have been administered in response to circulating vaccine-derived poliovirus type 2 (cVDPV2) outbreaks since 2021. Although infants are eligible to receive the vaccine from birth, the induction of intestinal mucosal immunity by nOPV2 in newborns has not been directly evaluated.

View Article and Find Full Text PDF

We report the emergence and evolution of a circulating vaccine-derived poliovirus type 1 (cVDPV1) outbreak in Israel, linked to a vaccine-associated paralytic poliomyelitis case. Whole genome sequencing revealed a strong genetic link between the Sabin-like poliovirus type 1 variant from the case and pre-VDPV1 and VDPV1 isolated from environmental samples collected in October 2024-April 2025, mostly in Jerusalem. Early detection was made possible by Israel's robust environmental surveillance and advanced sequencing technologies, enabling a rapid public health response.

View Article and Find Full Text PDF

Background: Reducing the risks of vaccine-derived polioviruses and vaccine-associated paralytic poliomyelitis motivated the development of novel types 1 and 3 oral poliovirus vaccines (nOPV1 and nOPV3, respectively), designed to have similar safety and immunogenicity and improved genetic stability (to reduce risk of reversion to neurovirulence) relative to types 1 or 3 Sabin-strain OPVs. We aimed to assess the safety and immunogenicity of nOPV1 and nOPV3 in healthy adults.

Methods: We did a first-in-human, observer-masked, multicentre, phase 1 randomised controlled trial in healthy adults at four centres in the USA.

View Article and Find Full Text PDF